Tadalafil vs Sildenafil — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Phosphodiesterase 5 Inhibitor

Tadalafil

Brand: ADCIRCA

First FDA approval: 2003-11-26

Phosphodiesterase 5 Inhibitor

Sildenafil

Brand: Revatio

First FDA approval: 1998-03-27

Lowest NADACAcquisition cost floor across all NDCs

$0.104Per unit

$0.053Per unit

Average NADACAcross all dosage forms and strengths

$1.11Up to $53.71

$6.18Up to $84.57

Generic manufacturersActive ANDA holders — FDA Orange Book

28111 total ANDAs filed

2571 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$161.4MFull year

$66.0MFull year

Part D claims (CY24)Total fills, all strengths

628K192K beneficiaries

1.1M369K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$257Per claim, all NDCs

$58Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1057Substantial friction

359Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes28 manufacturers

Yes25 manufacturers